Qurient Co

Qurient Co Intangible Assets

The Intangible Assets of Qurient Co (115180.KQ) as of Oct 26, 2026 is 1.43 B KRW. In the previous year, Intangible Assets was 1.65 B KRW — a change of -13.39% (lower).

Intangible Assets

1.43 BKRW

YoY

-13.39%

Last updated:

Intangible Assets of Qurient Co is 2024 1.43 B KRW. Intangible Assets of Qurient Co was 2023 1.65 B KRW. It decreases by -13.39% lower compared to the previous year.

The Qurient Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
118.00 M KRW
Jan 1, 2018
497.00 M KRW
Jan 1, 2019
501.00 M KRW
Jan 1, 2020
760.00 M KRW
Jan 1, 2021
1.60 B KRW
Jan 1, 2022
1.83 B KRW
Jan 1, 2023
1.65 B KRW
Jan 1, 2024
1.43 B KRW
The Qurient Co Intangible Assets history
YEARIntangible AssetsYoY
1.43 BKRW-13.39%
1.65 BKRW-9.75%
1.83 BKRW+14.62%
1.60 BKRW+109.90%
760.00 MKRW+51.70%
501.00 MKRW+0.80%
497.00 MKRW+321.19%
118.00 MKRW+84.38%
64.00 MKRW+4.92%
61.00 MKRW+134.62%
26.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Qurient Co Stock analysis

What does Qurient Co do? Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options. Qurient Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Qurient Co stock

Intangible Assets of Qurient Co is 1.43 B KRW in 2024.

Intangible Assets of Qurient Co changed from 1.65 B KRW to 1.43 B KRW, representing a -13.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Qurient Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Qurient Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Qurient Co

All Key Metrics — Qurient Co